title: Humanized, nonmitogenic OKT3 antibody, huOKT3 gamma(Ala-Ala): initial clinical experience.
authors.affiliation: Department of Surgery, Ben May Institute for Cancer Research, University of Chicago, Illinois, USA.
authors.forename: E S
authors.initials: ES
authors.lastname: Woodle
authors.forename: J A
authors.initials: JA
authors.lastname: Bluestone
authors.forename: R A
authors.initials: RA
authors.lastname: Zivin
authors.forename: L K
authors.initials: LK
authors.lastname: Jolliffe
authors.forename: J
authors.initials: J
authors.lastname: Auger
authors.forename: D
authors.initials: D
authors.lastname: Xu
authors.forename: J R
authors.initials: JR
authors.lastname: Thistlethwaite
mesh_terms: D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000628:therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D016853:Muromonab-CD3 / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016035:Pancreas Transplantation / Q000276:immunology*; D013997:Time Factors
chemical_list: D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; C112844:monoclonal antibody huOKT3(Ala-Ala)